Bacitracin - Generic Drug Details

What are the generic drug sources for bacitracin and what is the scope of freedom to operate?

Bacitracin is the generic ingredient in twenty branded drugs marketed by Pharmacia And Upjohn, Lilly, Padagis Us, Pharmaderm, Pharmafair, Combe, Naska, X Gen Pharms, Apothekernes, Paddock Llc, Casper Pharma Llc, Bausch And Lomb, Sciegen Pharms, Monarch Pharms, Dow Pharm, Glaxosmithkline, and Altana, and is included in thirty-seven NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-seven drug master file entries for bacitracin.

Summary for bacitracin

US Patents:	0
Tradenames:	20
Applicants:	17
NDAs:	37
Drug Master File Entries:	27
Clinical Trials:	31
Drug Prices:	Drug price trends for bacitracin
What excipients (inactive ingredients) are in bacitracin?	bacitracin excipients list
DailyMed Link:	bacitracin at DailyMed

See drug prices for bacitracin

Recent Clinical Trials for bacitracin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ohio State University	N/A
Cairo University	Early Phase 1
University of Turin, Italy	N/A

See all bacitracin clinical trials

Medical Subject Heading (MeSH) Categories for bacitracin

Anti-Bacterial Agents

Anti-Infective Agents, Local

Anatomical Therapeutic Chemical (ATC) Classes for bacitracin

D06AX	Other antibiotics for topical use
D06A	ANTIBIOTICS FOR TOPICAL USE
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D	Dermatologicals

J01XX	Other antibacterials
J01X	OTHER ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

R02AB	Antibiotics
R02A	THROAT PREPARATIONS
R02	THROAT PREPARATIONS
R	Respiratory system

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for bacitracin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Padagis Us	BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE	bacitracin zinc; hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	062166-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Casper Pharma Llc	LUMI-SPORYN	bacitracin zinc; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	050417-001	Approved Prior to Jan 1, 1982	AT	RX	Yes	No
Dow Pharm	NEO-POLYCIN	bacitracin zinc; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	060647-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sciegen Pharms	NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC	bacitracin zinc; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	065088-001	Feb 6, 2004		DISCN	No	No
Bausch And Lomb	NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC	bacitracin zinc; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	064064-001	Oct 30, 1995	AT	RX	No	Yes
Pharmafair	BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE	bacitracin zinc; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	062386-001	Sep 9, 1982		DISCN	No	No
Sciegen Pharms	NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE	bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	065213-001	Jul 25, 2012		DISCN	No	No

Market Dynamics and Financial Trajectory for Bacitracin

Last updated: February 20, 2026

How is the bacitracin market structured?

Bacitracin is an antibiotic used in topical formulations and occasionally in ophthalmic applications. Its primary market segments include healthcare-associated infections, topical wound care, and ophthalmology. Bacitracin is produced mainly by microbial fermentation, with several pharmaceutical companies holding manufacturing rights.

Market entry requires compliance with regulatory standards, including FDA approval in the U.S. and EMA approval in Europe, emphasizing quality controls and manufacturing practices. Patenting for bacitracin compounds has largely expired, leading to widespread generics production and price erosion.

What are the supply and demand factors affecting bacitracin?

Supply Factors

• Manufacturing capacity: Production depends on microbial fermentation infrastructure; capacity is limited by fermentation technology and raw material supply.
• Raw materials: Dependence on specific microbial strains and fermentation media influences supply stability.
• Regulatory hurdles: Import/export regulations and Good Manufacturing Practice (GMP) standards impact supply flow.
• Generic proliferation: The expiration of patents in the 1980s has resulted in multiple producers, increasing supply and reducing costs.

Demand Factors

• Clinical use: Topical infections continue to require bacitracin, especially in combination formulations.
• Alternative antibiotics: The availability of newer agents with broader spectrum and fewer resistance issues limits demand growth.
• Healthcare settings: Usage is concentrated in hospitals and clinics, where infection control protocols dictate antibiotic choices.
• Regulatory restrictions: Policies favoring antimicrobial stewardship limit unnecessary antibiotic prescriptions.

How has the market evolved over recent years?

The global bacitracin market has experienced stagnation and slight decline owing to:

• Shift to systemic antibiotics: Growing preference for systemic agents with broader coverage reduces topical antibiotic demand.
• Resistance concerns: Emergence of resistant strains limits use.
• Regulatory constraints: Compliance costs and tightened regulations restrict market expansion.
• Price competition: Widespread generic availability drives prices down, squeezing profit margins for manufacturers.

What are the revenue prospects and profitability trends?

Revenue Analysis

Estimates peg the global bacitracin market at approximately USD 200 million in 2022, with a compound annual growth rate (CAGR) of less than 1% projected through 2030 (MarketWatch, 2022).

Profitability Margins

Profit margins are variable; manufacturing costs are relatively low due to fermentation, but fierce price competition reduces profitability. Major producers report gross margins typically between 10-20%. R&D investments for new formulations are limited, reducing innovation-driven revenue.

Investment Considerations

• Companies with established fermentation capacity may maintain stable revenues.
• Entry into niche markets, like ophthalmic applications, may yield higher margins but with limited volume.
• Market consolidation is ongoing, with some producers shifting focus to newer antibiotics or alternative delivery systems.

Which regulatory policies influence the market?

• International agencies enforce strict quality standards for production.
• The US FDA classifies bacitracin as a prescription drug, influencing distribution channels.
• European regulations impose additional restrictions on antimicrobial use.
• Antimicrobial stewardship programs restrict unnecessary topical antibiotic use.

How do competitive forces shape market dynamics?

The market is highly competitive with numerous generic manufacturers. Limited patent protection results in price competition. Few branded formulations exist, mainly for specialized applications. Larger pharmaceutical companies focus less on bacitracin, favoring proprietary drugs with higher margins.

Key Challenges and Opportunities

Challenges

• Resistance development.
• Regulatory limitations.
• Competition from alternative antibiotics.
• Low profit margins.

Opportunities

• Developing combined formulations with other antibiotics.
• Expanding into niche applications like ophthalmic uses.
• Improving fermentation efficiency to lower production costs.

Summary table: Market Highlights

Aspect	Details
Market Size (2022)	USD 200 million
CAGR (2023–2030)	<1%
Major Players	GlaxoSmithKline, Teva, Mylan, generic manufacturers
Regulatory Status	Prescribed antibiotic, strict manufacturing standards
Price Trend	Declining due to generic competition
Innovation Opportunity	Niche formulations (e.g., ophthalmic)

Key Takeaways

• The global bacitracin market remains stable but stagnates due to generic competition and limited new applications.
• Revenue growth is constrained by antimicrobial resistance concerns and regulatory restrictions.
• Profit margins are thin, favoring manufacturers with cost-effective fermentation processes.
• Market expansion depends on niche applications and formulation innovations.
• Regulatory policies and antimicrobial stewardship efforts further restrict growth potential.

FAQs

Q1: What is current demand for bacitracin?
A1: Demand remains steady for topical and ophthalmic uses but faces decline due to competition from systemic antibiotics and resistance issues.

Q2: Which regions are leading in bacitracin production?
A2: North America and Europe dominate manufacturing, driven by established regulatory frameworks, with emerging generic producers in Asia.

Q3: Are there new formulations under development?
A3: Limited new formulations are in R&D, primarily aimed at niche applications like ophthalmology, to bypass market saturation.

Q4: How does antimicrobial resistance impact bacitracin?
A4: Resistance development diminishes clinical efficacy, leading to reduced prescription frequency and market contraction.

Q5: What are the prospects for profitability?
A5: Margins are compressed; profitability depends on production efficiency, market segment focus, and innovation in formulation.

---

References

1. MarketWatch. (2022). Global Bacitracin Market Report. Retrieved from https://www.marketwatch.com
2. U.S. Food and Drug Administration (FDA). (2022). Drug Approval and Regulation Data. Retrieved from https://www.fda.gov
3. European Medicines Agency (EMA). (2022). Pharmacovigilance and Marketing Authorizations. Retrieved from https://www.ema.europa.eu